$19.43K
1
2
$19.43K
1
2
Trader mode: Actionable analysis for identifying opportunities and edge
This market will resolve to "Yes" if there have been the specified amount or more confirmed cases of Measles (Rubeola) in humans in the territory of the United States of America in 2026, according to the CDC case counter by March 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No". The resolution source for this market will be the CDC Measles (Rubeola) counter 'Total Cases' in 2026 (see: https://www.cdc.gov/measles/data-research/index.html) at the resolution time. If the counter
Prediction markets estimate an 84% probability that the United States will see at least 1,400 confirmed measles cases by March 31, 2026. In simpler terms, traders collectively believe there is a roughly 5 in 6 chance this threshold will be met. This shows a high degree of confidence that case numbers will remain significantly elevated compared to recent years.
Two main factors are driving this pessimistic forecast. First, the U.S. is experiencing its largest measles outbreak in years. The CDC reported over 1,200 cases in 2024, and 2025 is on a similar trajectory, with hundreds of cases already confirmed in the first quarter. The current pace makes reaching 1,400 total cases by the end of March 2026 seem plausible.
Second, vaccination gaps are creating vulnerable populations. Measles is one of the most contagious viruses known, and communities with measles, mumps, and rubella (MMR) vaccination rates below 95% are at high risk for outbreaks. Recent clusters have been linked to declines in childhood vaccination, a trend that began before the COVID-19 pandemic but may have been worsened by it. These conditions allow the virus to spread more easily.
The primary signal will be the CDC's weekly updates on measles cases. A sustained high weekly case count through the rest of 2025 would solidify the current prediction. Conversely, a sharp decline in new outbreaks before the end of 2025 could lower the odds. There are no specific policy deadlines, but any major new public health campaigns or state-level mandates on school vaccinations could influence transmission rates and shift the market.
Prediction markets have a mixed record on specific numeric thresholds for disease outbreaks. They are generally good at sensing direction and scale based on current trends, but unexpected public health interventions can change outcomes. The 84% probability is not a guarantee. It reflects the clear and concerning trend line from 2024 continuing into 2025. The main limitation is that this forecast assumes no major, successful efforts to interrupt transmission in the next year, which is possible but currently seems unlikely to traders.
Prediction markets on Polymarket are pricing in an 84% probability that the United States will record at least 1,400 measles cases by March 31, 2026. This price indicates a strong consensus that a major outbreak is likely. With only 30 days until resolution, the market shows high conviction. However, the total trading volume of $19,000 is relatively thin, meaning a single large bet could still move the odds.
The high probability reflects a clear trend in U.S. public health data. The CDC reported 1,515 total measles cases in 2024, the highest annual number since 1992. Case counts for early 2026 are already tracking significantly ahead of last year's pace. This surge is directly linked to declining vaccination coverage. The CDC's 2023 report showed kindergarten MMR vaccination rates had fallen to 93.1%, below the 95% threshold needed for herd immunity. Specific outbreaks in under-vaccinated communities, particularly in major metro areas, are acting as consistent case drivers. The market is effectively betting that these epidemiological conditions will persist.
The primary factor that could lower the probability is aggressive public health intervention. If state or local health departments rapidly implement successful containment measures in active outbreak zones, the case trajectory could flatten. Conversely, the odds could move even higher if a large outbreak occurs in a densely populated city with low vaccination rates. The resolution depends on the CDC's official case counter, which may have a reporting lag. A last-minute data revision before the March 31 deadline is a minor risk, but the current count appears robust enough to make the 1,400-case threshold very likely to be met.
AI-generated analysis based on market data. Not financial advice.
This prediction market focuses on whether the United States will record a specified number of confirmed measles cases by March 31, 2026. Measles, also known as rubeola, is a highly contagious viral disease that was declared eliminated in the U.S. in 2000. The market resolves based on the official 'Total Cases' counter for 2026 maintained by the Centers for Disease Control and Prevention (CDC). The CDC's data is the definitive national record, tracking laboratory-confirmed infections reported by state health departments. Interest in this market stems from ongoing public health concerns about measles resurgence. Recent years have seen significant outbreaks linked to declining vaccination rates and international travel. The first quarter of 2026 will be a critical monitoring period, as measles cases often increase in late winter and early spring. Public health officials, policymakers, and healthcare providers closely watch these numbers as an indicator of vaccination coverage and outbreak potential. The outcome has implications for public health strategy and resource allocation.
Measles was a common childhood illness in the U.S. before a vaccine was introduced in 1963, causing an estimated 3 to 4 million cases annually. A major public health achievement occurred in 2000 when the CDC declared measles eliminated, meaning no continuous disease transmission for over 12 months. This success was attributed to the high coverage of the two-dose MMR (measles, mumps, rubella) vaccine. Elimination status has been maintained, but not without challenges. Significant outbreaks have occurred in the post-elimination era, often originating from unvaccinated travelers. A large outbreak in 2014, primarily linked to an amusement park in California, resulted in 667 cases across 27 states. The largest recent outbreak was in 2019, with 1,274 confirmed cases, the highest annual total since 1992. That outbreak was concentrated in close-knit communities with low vaccination rates in New York. These events demonstrate the persistent threat of measles reintroduction and the fragility of elimination status when vaccination coverage declines.
The number of measles cases by the end of March 2026 is a leading indicator of annual outbreak risk and the effectiveness of the nation's immunization shield. A high case count early in the year often predicts a larger annual total, requiring health departments to divert resources from other programs for outbreak containment. This includes costly activities like contact tracing, providing post-exposure prophylaxis, and public communication campaigns. Economically, a single measles case investigation can cost local health departments between $10,000 and $150,000. For hospitals, isolating suspected cases strains infection control resources. Politically, case numbers influence debates over school vaccination laws and non-medical exemption policies. Socially, outbreaks disrupt schools and communities, force quarantines on unvaccinated individuals, and can erode trust in public health institutions. High case counts also signal increased risk for severe complications, including pneumonia and encephalitis, particularly for infants too young for vaccination and immunocompromised individuals.
As of late 2024 and early 2025, measles transmission remains a active public health concern. The CDC reported a significant increase in cases in 2024 compared to the previous year. Several localized outbreaks occurred, including one in a Chicago migrant shelter. Health authorities continue to emphasize the importance of MMR vaccination, especially before international travel. The CDC issued a health alert in March 2024 noting the rise in cases and urging healthcare providers to be vigilant. Vaccination rates in some communities have not fully recovered from declines seen during the COVID-19 pandemic, creating pockets of susceptibility. Public health messaging focuses on catching up children who missed routine immunizations.
The CDC counts a case after a state or local health department confirms it through laboratory testing. Confirmation typically requires a positive blood test for measles IgM antibodies, a positive PCR test for measles virus RNA, or epidemiological linkage to a lab-confirmed case. All confirmed cases are reported to the CDC's National Notifiable Diseases Surveillance System.
The incubation period for measles is typically 10 to 14 days from exposure to the onset of fever. The rash usually appears a few days after the fever begins. Measles is one of the most contagious viruses known; it spreads through the air when an infected person coughs or sneezes. The virus can remain infectious in the air for up to two hours after an infected person leaves an area.
The measles component of the MMR vaccine is highly effective. One dose is about 93% effective at preventing measles. Two doses, which is the standard recommended schedule, are about 97% effective. Protection from the vaccine is long-lasting, likely for a lifetime.
Vaccination rates vary by state and community. According to the most recent CDC data for kindergarteners, states like Idaho, Ohio, and Georgia had MMR vaccination rates below 90% for the 2022-2023 school year. Exemption rates for philosophical or religious reasons are often higher in these states.
Common complications include ear infections, which occur in about 1 in 10 children, and diarrhea. More severe complications include pneumonia, which is the most common cause of death from measles in young children, and encephalitis, which can lead to permanent brain damage. For every 1,000 children who get measles, 1 to 3 will die from respiratory or neurologic complications.
Educational content is AI-generated and sourced from Wikipedia. It should not be considered financial advice.
2 markets tracked
No data available
| Market | Platform | Price |
|---|---|---|
| Poly | 84% |
| Poly | 55% |
No related news found
Add this market to your website
<iframe src="https://predictpedia.com/embed/aaw1B5" width="400" height="160" frameborder="0" style="border-radius: 8px; max-width: 100%;" title="Measles cases in U.S. by March 31?"></iframe>